Rakesh Dixit
President & Chief Executive Officer Bionavigen Oncology
Seminars
Monday 8th March 2027
Opportunities for Improving the Translational Safety of ADCs From NHPs to Humans
- Identifying which toxicities are reasonably predictable from animal or in vitro studies
- Discussing toxicities that are still difficult to understand and where things are “falling apart”
- Exploring what can be done to further enhance the understanding of ADC toxicities, including focusing on key toxicities such as ocular and lung regions
